Recruiting
Phase 2

VERVE-102

Sponsor:

Verve Therapeutics, Inc.

Code:

NCT07839936

Conditions

Atherosclerosis

Cardiovascular Disease

Hypercholesterolemia

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Interventions

VERVE-102

Placebo

Study Details

Brief summary:

The purpose of this study is to measure the change in bad cholesterol (LDL-C) with VERVE-102 compared to placebo in adults who have plaque buildup in their arteries or are at high risk of developing it.

Conditions

Atherosclerosis

Cardiovascular Disease

Hypercholesterolemia

Study ID

NCT07839936

Start date

Sep 24, 2026

Status verified date

Nov, 2026

Completion date

Mar, 2030

Anticipated

Primary completion date

Aug, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Established atherosclerotic cardiovascular disease (ASCVD) and/or at a high risk of ASCVD

Exclusion Criteria:

  • History of confirmed or suspected homozygous familial hypercholesterolemia (HoFH)
  • Chronic liver disease
  • Current treatment with PCSK9 inhibitor or prior treatment within specified timeframe

Study Design

Enrollment

175 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: VERVE-102 Dose 1

Participants will receive a single dose of VERVE-102 intravenously (IV)

experimental: VERVE-102 Dose 2

Participants will receive a single dose of VERVE-102 IV

experimental: VERVE-102 Dose 3

Participants will receive a single dose of VERVE-102 IV

placebo comparator: Placebo

Participants will receive a single dose of placebo IV

Interventions

VERVE-102

Administered IV

Placebo

Administered IV

Primary outcome measure

  • Percent Change from Baseline in LDL-C [ Time Frame: Baseline, Day 90 ]

Central Contacts and Locations

Central contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

317-615-4559LillyTrials@Lilly.com

Physicians interested in becoming principal investigators please contact

clinical_inquiry_hub@lilly.com

Locations

Epic Medical Research

Recruiting

DeSoto, Texas, United States, 75115

More Information

Sponsor

Verve Therapeutics, Inc.

Last update posted

Nov 10, 2026

Last verified

Nov, 2026

Keywords

  • Heterozygous Familial Hypercholesterolemia
  • LDL cholesterol
  • High cholesterol
  • Cardiovascular risk factors
  • Coronary Artery Disease
  • Heart attack
  • Stroke
  • Base editing

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-11. This information was provided to ClinicalTrials.gov by Verve Therapeutics, Inc. on 2026-11-10. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.